Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

240 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pretomanid-resistant tuberculosis.
Koehler N, Andres S, Merker M, Dreyer V, John A, Kuhns M, Krieger D, Choong E, Verougstraete N, Zur Wiesch PA, Wicha SG, König C, Kalsdorf B, Sanchez Carballo PM, Schaub D, Werngren J, Schön T, Peloquin CA, Schönfeld N, Verstraete AG, Decosterd LA, Aarnoutse R, Niemann S, Maurer FP, Lange C. Koehler N, et al. Among authors: aarnoutse r. J Infect. 2023 May;86(5):520-524. doi: 10.1016/j.jinf.2023.01.039. Epub 2023 Feb 2. J Infect. 2023. PMID: 36738862 No abstract available.
Perspective for Precision Medicine for Tuberculosis.
Lange C, Aarnoutse R, Chesov D, van Crevel R, Gillespie SH, Grobbel HP, Kalsdorf B, Kontsevaya I, van Laarhoven A, Nishiguchi T, Mandalakas A, Merker M, Niemann S, Köhler N, Heyckendorf J, Reimann M, Ruhwald M, Sanchez-Carballo P, Schwudke D, Waldow F, DiNardo AR. Lange C, et al. Among authors: aarnoutse r. Front Immunol. 2020 Oct 8;11:566608. doi: 10.3389/fimmu.2020.566608. eCollection 2020. Front Immunol. 2020. PMID: 33117351 Free PMC article. Review.
Optimising pyrazinamide for the treatment of tuberculosis.
Zhang N, Savic RM, Boeree MJ, Peloquin CA, Weiner M, Heinrich N, Bliven-Sizemore E, Phillips PPJ, Hoelscher M, Whitworth W, Morlock G, Posey J, Stout JE, Mac Kenzie W, Aarnoutse R, Dooley KE; Tuberculosis Trials Consortium (TBTC) and Pan African Consortium for the Evaluation of Antituberculosis Antibiotics (PanACEA) Networks. Zhang N, et al. Among authors: aarnoutse r. Eur Respir J. 2021 Jul 20;58(1):2002013. doi: 10.1183/13993003.02013-2020. Print 2021 Jul. Eur Respir J. 2021. PMID: 33542052 Free PMC article. Clinical Trial.
High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre.
Seijger C, Hoefsloot W, Bergsma-de Guchteneire I, Te Brake L, van Ingen J, Kuipers S, van Crevel R, Aarnoutse R, Boeree M, Magis-Escurra C. Seijger C, et al. Among authors: aarnoutse r. PLoS One. 2019 Mar 14;14(3):e0213718. doi: 10.1371/journal.pone.0213718. eCollection 2019. PLoS One. 2019. PMID: 30870476 Free PMC article.
Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokinetics.
Ruth MM, Raaijmakers J, van den Hombergh E, Aarnoutse R, Svensson EM, Susanto BO, Simonsson USH, Wertheim H, Hoefsloot W, van Ingen J. Ruth MM, et al. Among authors: aarnoutse r. Clin Microbiol Infect. 2022 Mar;28(3):448.e1-448.e7. doi: 10.1016/j.cmi.2021.07.015. Epub 2021 Jul 28. Clin Microbiol Infect. 2022. PMID: 34332109 Free article.
The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations.
Bowness R, Boeree MJ, Aarnoutse R, Dawson R, Diacon A, Mangu C, Heinrich N, Ntinginya NE, Kohlenberg A, Mtafya B, Phillips PP, Rachow A, Plemper van Balen G, Gillespie SH. Bowness R, et al. Among authors: aarnoutse r. J Antimicrob Chemother. 2015 Feb;70(2):448-55. doi: 10.1093/jac/dku415. Epub 2014 Oct 25. J Antimicrob Chemother. 2015. PMID: 25344806
240 results